135 related articles for article (PubMed ID: 32721854)
1. Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Kawatkar SP; Barlaam B; Kemmitt P; Simpson I; Watson D; Wang P; Lamont S; Su Q; Boiko S; Ikeda T; Patel J; Pike A; Pollard H; Read J; Sarkar U; Wang H; Wen Q; Yan Z; Dowling JE; Dry H; Edmondson SD
Bioorg Med Chem Lett; 2020 Sep; 30(18):127393. PubMed ID: 32721854
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new Syk inhibitors through structure-based virtual screening.
Huang Y; Zhang Y; Fan K; Dong G; Li B; Zhang W; Li J; Sheng C
Bioorg Med Chem Lett; 2017 Apr; 27(8):1776-1779. PubMed ID: 28268139
[TBL] [Abstract][Full Text] [Related]
3. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases.
Wang T; Block MA; Cowen S; Davies AM; Devereaux E; Gingipalli L; Johannes J; Larsen NA; Su Q; Tucker JA; Whitston D; Wu J; Zhang HJ; Zinda M; Chuaqui C
Bioorg Med Chem Lett; 2012 Mar; 22(5):2063-9. PubMed ID: 22305584
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
Lee SJ; Choi JS; Han BG; Kim HS; Song HJ; Lee J; Nam S; Goh SH; Kim JH; Koh JS; Lee BI
FEBS J; 2016 Oct; 283(19):3613-3625. PubMed ID: 27504936
[TBL] [Abstract][Full Text] [Related]
5. Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models.
Kaur M; Silakari O
SAR QSAR Environ Res; 2016 Jun; 27(6):469-99. PubMed ID: 27431536
[TBL] [Abstract][Full Text] [Related]
6. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
7. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
[TBL] [Abstract][Full Text] [Related]
8. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Barker MD; Liddle J; Atkinson FL; Wilson DM; Dickson MC; Ramirez-Molina C; Lewis H; Davis RP; Somers DO; Neu M; Jones E; Watson R
Bioorg Med Chem Lett; 2018 Nov; 28(21):3458-3462. PubMed ID: 30249354
[TBL] [Abstract][Full Text] [Related]
11. 3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.
Shen J; Li X; Zhang Z; Luo J; Long H; Tu Z; Zhou X; Ding K; Lu X
Chem Biol Drug Des; 2016 Nov; 88(5):690-698. PubMed ID: 27264434
[TBL] [Abstract][Full Text] [Related]
12. Rational design of highly selective spleen tyrosine kinase inhibitors.
Lucas MC; Goldstein DM; Hermann JC; Kuglstatter A; Liu W; Luk KC; Padilla F; Slade M; Villaseñor AG; Wanner J; Xie W; Zhang X; Liao C
J Med Chem; 2012 Dec; 55(23):10414-23. PubMed ID: 23151054
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
Hoemann M; Wilson N; Argiriadi M; Banach D; Burchat A; Calderwood D; Clapham B; Cox P; Duignan DB; Konopacki D; Somal G; Vasudevan A
Bioorg Med Chem Lett; 2016 Nov; 26(22):5562-5567. PubMed ID: 27789138
[TBL] [Abstract][Full Text] [Related]
14. Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
Barlaam B; Boiko S; Boyd S; Dry H; Gingipalli L; Ikeda T; Johnson T; Kawatkar S; Lorthioir O; Pike A; Pollard H; Read J; Su Q; Wang H; Wang H; Wang L; Wang P; Edmondson SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127523. PubMed ID: 32877741
[TBL] [Abstract][Full Text] [Related]
15. Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor.
Wang C; Wang X; Li Y; Wang T; Huang Z; Qin Z; Yang S; Xiang R; Fan Y
Bioorg Chem; 2020 Jan; 95():103547. PubMed ID: 31911307
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-ε kinases.
Johannes JW; Chuaqui C; Cowen S; Devereaux E; Gingipalli L; Molina A; Wang T; Whitston D; Wu X; Zhang HJ; Zinda M
Bioorg Med Chem Lett; 2014 Feb; 24(4):1138-43. PubMed ID: 24462666
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Hirabayashi A; Mukaiyama H; Kobayashi H; Shiohara H; Nakayama S; Ozawa M; Tsuji E; Miyazawa K; Misawa K; Ohnota H; Isaji M
Bioorg Med Chem; 2008 Oct; 16(20):9247-60. PubMed ID: 18823784
[TBL] [Abstract][Full Text] [Related]
18. Identification of type-II inhibitors using kinase structures.
Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
[TBL] [Abstract][Full Text] [Related]
19. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
[TBL] [Abstract][Full Text] [Related]
20. Identification of natural product-based effective inhibitors of spleen tyrosine kinase (SYK) through virtual screening and molecular dynamics simulation approaches.
Ali T; Anjum F; Choudhury A; Shafie A; Ashour AA; Almalki A; Mohammad T; Hassan MI
J Biomol Struct Dyn; 2024 Apr; 42(7):3459-3471. PubMed ID: 37261484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
